Details about diet pills are explained below in detail.
Details about diet pills are explained below in detail.
Belviq is a new prescription weight loss drug, one of only two new weight loss drugs approved by the FDA in the last 13 years. Belviq acts in the brain as a serotonin 2C receptor agonist.
Belviq is indicated for chronic weight management in adult patients with aninitial body mass index (BMI) of:
one weight-related comorbid condition (e.g., hypertension,dyslipidemia, type 2 diabetes)
Belviq is provided as blue, film-coated, 10 mg tablets. The recommended dose of BELVIQ is 10 mg administered orally twice daily. Dose is unrelated to meal time.
Most common adverse reactions (greater than 5%) in non-diabetic patients are headache, dizziness, fatigue, nausea, dry mouth, and constipation, and in diabetic patients are hypoglycemia, headache, back pain, cough, and fatigue.
It is a unique combination of two well known drugs, phentermine and topiramate, but new formulation.
The main difference is “summation of effect without summation of side effects.”
For that reason at Allergy and weight Loss center and Concord weight loss center we use Qsymia for short and long term weight loss
Phentermine is appetite suppressant. Topiramate acts on the brain neurotransmitters. This medication acts on serotonin , a neurotransmitter that has been implicated
in depression
Phentermine is an appetite suppressant. It triggers the release of norepinephrine in the brain, which increases blood concentrations of leptin, an appetite-regulating hormone.
Topiramate, commonly known as Topamax, is prescribed as an anticonvulsant and migraine medication. It can aid in weight loss by increasing the feeling of being full, making foods taste less appealing and increasing calorie expenditure.
Read more: http://www.foxnews.com/health/2012/07/25/all-need-to-know-about-qsymia/#ixzz2N1Ta1wLX
Qsymia is indicated for weight loss if
Qsymia is available as phentermine hydrochloride (as the free base)/topiramate extended-release gelatin capsules in the following strengths and colors:
Qsymia™ is initiated with a starting dose of 3.75 mg/23 mg† that is increased after 14 days of treatment to a recommended dose of 7.5 mg/46 mg. After 30 days on this dose, the patient should be evaluated and the dose titrated based on response.
To begin, your doctor will write 2 prescriptions:
If weight loss is less than 3%, discontinue Qsymia or escalate the dose
To escalate dose, prescribe:
http://www.qandmesupport.com/
Contrave, the new prescription weight loss drug to be approved by the FDA in 2014.
Contrave joins Qsymia (phentermine and topiramate) and Belviq (lorcaserin). Both were approved in 2012.
Contrave combines two drugs already on the market:
Bupropion, the same active ingredient as some other antidepressant medications ( WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL and APLENZIN)
Naltrexone is marketed in generic form as naltrexone hydrochloride, and marketed under the trade names Revia and Depade. In some countries including the United States, a once-monthly extended-release injectable formulation is marketed under the trade name Vivitrol. Also in the United States, Methylnaltrexone Bromide, a closely related drug, is marketed as Relistor, for the treatment of opioid induced constipation.
Naltrexone should not be confused with naloxone nor nalorphine, which are used in emergency cases of opioid overdose.
Naltrexone and bupropion have effects on two separate areas of the brain involved in the regulation of food intake:
http://www.contrave.com/Images/howto-dosing-table.png
More information about Contrave:
Fullness
Satiety (satisfaction of a meal)
Hunger
At our clinic, Anita Bhat, MD and Jyoti Bhat, MD are board certified endocrinologists with expertise in using Saxenda category of drugs.